Dx&Vx said Friday that its U.K. affiliate Oxford Vacmedix reported on its website Tuesday (local time) that its cancer vaccine candidate OVM-200 met both primary and secondary endpoints in a phase 1 clinical trial.
Oxford Vacmedix is a U.K.-based biotech firm of which Dx&Vx is the largest shareholder.
According to Oxford Vacmedix, the first-in-human, multicenter, open-label phase 1 study enrolled 36 patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), ovarian cancer, and prostate cancer. The trial met its primary endpoint of safety, as well as secondary endpoints including immunogenicity and dose optimization.
It also reported early signs of clinical activity, including stable disease in NSCLC and prostate-specific antigen (PSA) responses in prostate cancer patients.
Oxford Vacmedix said OVM-200 demonstrated a favorable safety profile, with no serious adverse drug reactions or dose-limiting toxicities observed. Adverse events were limited to Grade 1 injection-site reactions. In terms of immunogenicity, the vaccine induced robust antibody and T-cell responses. Based on these findings, a 2 mg dose was selected as optimal for the phase 1b expansion study, with up to 11 doses administered.
OVM-200 is a therapeutic cancer vaccine developed using the company’s proprietary recombinant overlapping peptide (ROP) platform. The candidate targets survivin, a tumor-associated antigen, and is being developed for multiple solid tumors, including prostate, ovarian, and lung cancers.
Oxford Vacmedix described the phase 1 results as a key milestone supporting the clinical potential of its ROP platform.
The company is currently pursuing Series B financing and preparing to advance OVM-200 into phase 2 development. In parallel, it is expanding its pipeline, including OVM-100, a vaccine candidate targeting human papillomavirus (HPV).
Dx&Vx said it plans to leverage the phase 1 data to refine its phase 2 trial design in Asia, aiming to accelerate global licensing and enhance shareholder value.
“The achievement of safety, immunogenicity, and dose-selection endpoints, along with early efficacy signals for OVM-200, strengthens our investment thesis,” a Dx&Vx official said. “We anticipate substantial appreciation of our equity position as we advance clinical and commercialization stages.”
Lee Han-soo
댓글
0